Today: 19 July 2026
MongoDB (MDB) stock drops nearly 5% to start 2026 — here’s what investors are watching next
3 January 2026
1 min read

MongoDB (MDB) stock drops nearly 5% to start 2026 — here’s what investors are watching next

NEW YORK, Jan 2, 2026, 20:46 ET — Market closed

  • MongoDB closed down 4.8% at $399.65 on Friday, lagging a selloff in software stocks.
  • The software-sector ETF IGV fell 2.9% on the day, highlighting pressure on high-growth tech.
  • MongoDB’s next earnings are estimated for March 4 after the close, based on past reporting schedules, according to MarketBeat.

MongoDB, Inc. (MDB) shares closed down 4.8% at $399.65 on Friday, deepening a pullback across software stocks as investors trimmed risk on the first trading day of 2026.

The decline matters because MongoDB has been one of the stronger large-cap software names in recent months, a setup that can magnify moves when sentiment turns.

High-growth software stocks often trade on expectations for future cash flows, which can make them more sensitive than the broader market to shifts in risk appetite.

The iShares Expanded Tech-Software Sector ETF fell 2.9% on the day, while the Nasdaq 100 tracking fund QQQ slipped about 0.2% and the S&P 500 tracker SPY rose about 0.2%.

MongoDB traded between $392.86 and $432.70 on Friday, and volume topped 2.5 million shares, above its average, market data showed.

Some analysts stayed positive despite the volatility. Mark Cash at Raymond James called MongoDB one of the “most strategically important independent database platforms,” according to a note cited by Insider Monkey.

MarketBeat’s tally of 41 analyst ratings puts MongoDB at “Moderate Buy” and shows an average 12-month price target of $414.97 — about 4% above Friday’s close. MarketBeat

Investors remain anchored to MongoDB’s last quarterly report. The company posted third-quarter fiscal 2026 revenue of $628.3 million, up 19% from a year earlier, and said Atlas — its managed cloud database service — made up about 75% of total revenue.

On an earnings-per-share basis — a measure of profit allocated to each share — MongoDB reported EPS of $1.32 on Dec. 1, beating a consensus estimate of $0.79, according to MarketBeat’s earnings summary.

The next key catalyst is the next set of results. MarketBeat estimates MongoDB will report fourth-quarter figures on March 4 after the market closes, based on past reporting schedules.

Before next session, traders will watch whether MongoDB can regain the $400 level after dipping below it on Friday; the stock’s 52-week high is $441.70 and its low is $170.30.

Before next session, investors will be focused on whether Atlas growth and customer spending trends stay resilient — a key watchpoint for subscription and usage-driven cloud software models.

Before next session, any further weakness in the broader software group could keep pressure on MongoDB, after IGV’s nearly 3% drop on Friday.

In extended trading — buying and selling outside the regular 9:30 a.m. to 4:00 p.m. ET session — MongoDB was little changed at $399.50 as of 7:59 p.m. ET, MarketBeat data showed.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • Neurocrine Biosciences (NBIX) Stock Fair Value and Performance in Focus
    July 19, 2026, 3:59 PM EDT. Neurocrine Biosciences (NBIX) is viewed as near fairly valued, with shares trading at a P/E ratio of 25.7x versus a fair value estimate of 26.0x. The stock has increased 73.4% over five years and posted a 29.4% gain in the past year, though this trails some competitors. Valuation signals are mixed, with about half indicating the stock could be expensive. Investors are assessing the resilience of cash flows from current therapies alongside operational risks. Growth prospects are supported by a broad pipeline, including late-stage assets and early commercial progress, yet policy changes and concentration risks are present. The overall assessment shows a valuation that reflects tempered expectations for Neurocrine's earnings potential and profitability.
UnitedHealth stock rises today as 2026 opens; UNH holds gains after hours with earnings ahead
Previous Story

UnitedHealth stock rises today as 2026 opens; UNH holds gains after hours with earnings ahead

Blackbaud stock slides nearly 6% to start 2026 as investors eye jobs data and mid-Feb earnings window
Next Story

Blackbaud stock slides nearly 6% to start 2026 as investors eye jobs data and mid-Feb earnings window

Go toTop